Lycera Secures $29,892,748 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=34e39712-ee89-4c9e-b14d-b8f09f530ae4 - Date
6/22/2015 - Company Name
Lycera - Mailing Address
2800 Plymouth Rd. Ann Arbor, MI 48109 USA - Company Description
Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. - Website
http://www.lycera.com - Transaction Type
Venture Equity - Transaction Amount
$29,892,748 - Transaction Round
Series B - Proceeds Purposes
Amount includes Conversion of Convertible Promissory Notes for Series B Preferred Stock and the purchase of Series B-1 Preferred Stock for cash. Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities. - M&A Terms
- Venture Investor
